Rockefeller Capital Management’s Cullinan Therapeutics CGEM Stock Holding History
Bought
Maintained
Sold
Other funds holding CGEM
LCM
KCM
SL
Rockefeller Capital Management's CGEM Position: Q3 2026 in Review
Rockefeller Capital Management increased its Cullinan Therapeutics (CGEM) stake by 130% in Q3 2026, buying an estimated $16.1K and bringing the position to 1,491 shares worth $22.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3842.
Rockefeller Capital Management first reported a position in CGEM in Q2 2022 and has held it in 4 quarters since. 182 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.
- Rockefeller Capital Management held 1,491 shares of Cullinan Therapeutics worth $22.9K as of Q3 2026.
- Rockefeller Capital Management bought 842 Cullinan Therapeutics shares in Q3 2026, an estimated $16.1K.
- Cullinan Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3842 holding.
- Rockefeller Capital Management first reported a position in Cullinan Therapeutics in Q2 2022 and has held it in 4 quarters since.
- 182 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.